Specifically, de novo pathogenic variants in the BRAF (~75%) [4,7,8], MAP2K1 and MAP2K2 (~25%) [4,7] and KRAS genes (˂2%) [4,8] have been recognised as being causative of CFCS [4,8]. This evidence concerns the gene KRAS and cardiofaciocutaneous syndrome 1.